Improved treatment of cancer using TLR3 agonists

Details for Australian Patent Application No. 2005305604 (hide)

Owner Institut Gustave Roussy

Inventors Zitvogel, Laurence; Sabourin, JeanChristophe; Andre, Fabrice

Agent Davies Collison Cave

Pub. Number AU-B-2005305604

PCT Pub. Number WO2006/054177

Priority 11/144,322 03.06.05 US; PCT/ IB2004/004093 19.11.04 IB

Filing date 18 November 2005

Wipo publication date 26 May 2006

Acceptance publication date 12 May 2011

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

C12N 15/117 (2010.01) Mutation or genetic engineering - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

Event Publications

24 May 2007 PCT application entered the National Phase

  PCT publication WO2006/054177 Priority application(s): WO2006/054177

12 May 2011 Application Accepted

  Published as AU-B-2005305604

8 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005305605-Thin IOL

2005305599-Composition for amplifying nucleic acids